Sinonasal Therapies in Cystic Fibrosis Patients on Highly Effective Modulator Therapy

This study is looking at whether people with Cystic Fibrosis (CF) who are taking highly effective modulator therapy (HEMT) can safely stop using certain nose treatments. These treatments include nasal saline irrigation (with or without steroids). Researchers want to see if stopping these treatments changes your nose health, measured by your Lund Kennedy Score, lung function, and body mass index (BMI) over 12 weeks. You can join if you are 18 or older, have CF and are on HEMT, have a history of chronic rhinosinusitis (a long-term sinus condition), and currently use topical nasal irrigations. The study aims to understand if these nose treatments are still needed once you are on HEMT.

Study design
This is an interventional study with a planned enrollment of 64 participants. It compares continuing nasal saline irrigation with or without steroid to stopping it.
What's involved
Participants will either stop or continue using their nasal saline irrigation with or without steroid. Measurements for Lund Kennedy Score, pulmonary function, and BMI will be taken at the beginning and after 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks, with measurements taken at baseline and at the end of this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06996951

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

Recruiting
PHASE3Ages 18+InterventionalTreatment
Indiana University
~64 participants
Updated 2025-12-16 on ClinicalTrials.gov
What's tested:STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROIDCONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Lund Kennedy Score
Measured over Baseline, 12 weeks
+6 more outcomes measured
Cystic Fibrosis (CF)
Chronic Rhinosinusitis (CRS)
1 sites across 1 states
Indiana1
  • Elisa Illing, MD · PRINCIPAL_INVESTIGATOR · Indiana University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 or older
Cystic Fibrosis diagnosis on HEMT
History of chronic rhinosinusitis
Using topical nasal irrigations +/- additives (steroids, antibiotics)

Exclusion

Below age of 18 years old
Cystic Fibrosis patient NOT on highly effective modulator therapy
Pregnant patients
Not currently using topical nasal irrigations +/- additives (steroids, antibiotics)
History of sinonasal or nasopharyngeal tumors
Active sinonasal infection or pulmonary infection
Admission to hospital for pulmonary exacerbation within last 3 months
Oral antibiotics within last one month for upper respiratory or lower respiratory infection
  • Change in Lund Kennedy ScoreBaseline, 12 weeks

    Nasal Endoscopy will be performed in the clinic to evaluate the sinonasal cavities using the Lund Kennedy scoring system. The Lund-Kennedy endoscopic score grades the severity of chronic rhinosinusitis (CRS) based on findings from five areas: polyps, discharge, edema, scarring, and crusting, with each graded on a scale of 0 to 2 for each nostril, resulting in a total possible score of 20. A higher score indicates more severe disease.

  • Change in Pulmonary Function TestingBaseline, 12 weeks

    PULMONARY FUNCTION TESTING WILL BE PERFORMED WITH THE FEV1/FVC , CALCULATED. A lower score means poorer lung function.

  • Change in Body Mass Index (BMI)Baseline, 12 weeks

    BMI will be calculated as weight (kg) / height (m)2

  • Change in Health Care UtilizationBaseline, 12 weeks

    Health Care Utilization will be measured though a grouped analysis for additional doctor visits, hospital admissions, and use of antibiotics and oral steroids.

  • Change in Sinonasal Outcome Test 22 Questionnaire (SNOT-22) ScoreBaseline, 12 weeks

    The SNOT-22 measures nasal symptoms and social/emotional consequences of rhinosinusitis, rated on a scale of 0 (no problem) to 5 (problem is as bad as it can be). Scores may range from 0 to 110, with higher scores indicating worse sinus symptoms

  • Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) ScoreBaseline, 12 weeks

    The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a disease-specific health-related quality of life (HRQOL) measure for children, adolescents and adults with cystic fibrosis (CF). It is a profile measure of HRQOL with several different domains. The Cystic Fibrosis Questionnaire-Revised (CFQ-R) application calculates the score derived from the CFQ-R, on a 0-100 scale with higher scores indicating better HRQoL.

  • Change in Patient Health Questionnaire-9 (PHQ-9) ScoreBaseline, 12 weeks

    The PHQ-9 measures severity of depression. Potential scores may range from 0 - 27 with higher scores indicating more severe depression.